半導體板塊繼續走弱 疫情致半導體行業承壓
格隆匯4月13日丨半導體板塊午後繼續走弱,聞泰科技一度跌停,博通集成、東軟載波、通富微電等多股紛紛走弱。

受新冠肺炎疫情的影響,原本將進入上行期的半導體行業又面臨不確定性,收入或將下滑。主流機構已紛紛下調2020年半導體行業市場表現,其中市場調研機構Gartner於4月10日預計,受疫情影響,2020年全球半導體行業收入為4154億美元,將下滑0.9%。
另一市場調研機構IDC在3月份就表示,2020年全球半導體行業有80%的概率將迎來大幅縮水,而不是此前預計的小幅增長2%。不過,該機構稱仍有20%的機率實現快速、強勁的反彈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.